Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00454-5/abstract?utm_campaign=update-langas&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_langas&_hsenc=p2ANqtz-_KLkoUTr3X97DaBO5r99M4hve9Li__PkDH2tXo2msGUMhDN2YjsCu_-GjsyyU-JbZlob7hz5-SCoWiwkfJ452yCXWEDQ&_hsmi=298898417&utm_content=298831855&utm_source=hs_email